The Suunto Race 2 is a fantastic hardware upgrade, solidifying the brand's impressive comeback in recent years. The larger AMOLED display is stunning, the battery life is outstanding, and the GPS ...

Suunto has introduced the Vertical 2, the latest model in its adventure watch lineup. It is built for extreme expeditions and daily outdoor use. The new watch features a redesigned optical heart rate ...

Novo Nordisk (NYSE:NVO) shares have moved little in recent sessions, with investors taking a wait-and-see approach. Market participants are weighing the company's recent performance metrics against ...

Novo Nordisk may be breaking Heartseed's heart. As part of a company-wide restructuring under new CEO Maziar Mike Doustdar, the big pharma has axed a cell therapy collaboration with Heartseed worth ...

After another dismal quarter for Novo Nordisk A/S shares, investors are looking to an experimental treatment of the most common form of dementia to help spark a revival. The Danish drugmaker is ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, the weight-loss treatment Wegovy and type 2 diabetes therapy Ozempic. He ...

FILE PHOTO: A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/File Photo (Reuters) -Novo Nordisk has cut ...

Novo Nordisk licensed a clinical-stage MASP-3 inhibitor from Omeros. Omeros is eligible to receive $340 million upfront, royalties, and up to $2.1 billion in milestone payments. Omeros' cash balance ...

LONDON/COPENHAGEN, Oct 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, as the obesity drugmaker faces ...

Novo Nordisk has earned important label expansions this year. The company's pipeline progress should lead to more regulatory wins. Regulatory changes in the U.S. could also benefit the drugmaker. The ...

Under the terms of the agreement, Novo Nordisk will obtain exclusive global rights to develop and commercialize zaltenibart across all indications. Omeros is set to receive $340 million in upfront and ...